Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Clinical trial NCT05384587 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05384587
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-11
- Primary completion
- 2025-08-13
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.